US Patent

US9192615 — Method for the treatment of acne and certain dosage forms thereof

Formulation · Assigned to Medicis Pharmaceutical Corp · Expires 2031-11-17 · 6y remaining

Vulnerability score 31/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects specific oral dosage forms of minocycline hydrochloride containing 65 mg or 115 mg of minocycline.

USPTO Abstract

An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/−0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/−0.2% hydroxypropoxylated.

Drugs covered by this patent

Patent Metadata

Patent number
US9192615
Jurisdiction
US
Classification
Formulation
Expires
2031-11-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Medicis Pharmaceutical Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.